Robeauté announced it raised $28 million to support the development of its neurosurgical microrobot technology. Plural, Cherry Ventures and Kindred Ventures led the financing. Other investors included LocalGlobe and Think.Health, plus existing investors APEX Ventures, participated. Brainlab contributed a strategic investment.
Paris-based Robeauté plans to use the funds to continue development and start human trials in 2026. It intends to set up U.S. operations ahead of FDA approval and full go-to-market efforts as well.
Related: Alleviant Medical secures $90m to launch pivotal aortic stent trial
The company develops microrobots that come in at the size of a grain of rice. They can move along curved routes through the brain’s extracellular matrix to safely reach multiple sites of interest and carry out the required tasks. According to a news release, the company’s tiny, modular medical devices can embark on specific missions depending on the pathology.
Robeauté says the devices could prove ideal for delivering molecules, implanting electrodes and collecting cell or live-data samples through sensors. This could transform the understanding and ability to treat neuropathologies, the company says. The technology is currently in animal studies as a biopsy tool, with the company’s sights set on later use for treatment and real-time monitoring.
Brainlab’s strategic investment also supports the company’s entrance into the U.S. It plans to pursue FDA approval before pursuing a regulatory nod in Europe.
“We’re creating microrobots that will bring unparalleled access to the brain with personalized, precision medicine that can transform treatments and patient outcomes,” Bertrand Duplat, Robeauté co-founder and CEO said. “Over the past eight years, we’ve built a world-class team of experts, filed over 50 patents and commenced animal trials. This new funding from some of Europe’s leading investors will take us to the next level as part of our mission to empower neurosurgeons or neurospecialists with the tools to make a difference.”
